AK002
Sponsors
Allakos Inc.
Conditions
Atopic DermatitisAtopic KeratoconjunctivitisChronic UrticariaEosinophilic DuodenitisEosinophilic GastritisEosinophilic GastroenteritisHealthyIndolent Systemic Mastocytosis
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
CompletedNCT02808793
Start: 2016-06-30End: 2018-12-31Updated: 2019-03-13
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants
CompletedNCT02859701
Start: 2016-08-31End: 2017-05-17Updated: 2017-09-26
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
CompletedNCT03379311
Start: 2018-02-26End: 2019-08-08Updated: 2019-08-29
Phase 2
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
CompletedNCT03436797
Start: 2018-01-23End: 2020-04-06Updated: 2024-03-04
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
CompletedNCT03496571
Start: 2018-07-18End: 2019-06-24Updated: 2024-01-19
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
CompletedNCT03664960
Start: 2018-11-14End: 2021-11-02Updated: 2024-02-28
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
TerminatedNCT05155085
Start: 2022-06-27End: 2024-04-17Updated: 2024-10-15
Phase 3
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
CompletedNCT04856891
Start: 2021-05-20End: 2023-01-09Updated: 2024-01-02
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
WithdrawnNCT05152563
Start: 2021-12-31End: 2022-01-20Updated: 2023-03-03